GlaxoSmithKline unveils positive data from HIV drug study
7th Mar 2013 08:08
ViiV Healthcare, a global specialist HIV company set up by GlaxoSmithKline in 2009, has announced positive 24-week data from its Phase III Sailing study, which has investigated the effects of its dolutegravir treatment, a type of integrase inhibitor, in patients with HIV-1 who are failing on current
Read moreTuesday newspaper round-up: GlaxoSmithKline, Credit crunch, HSBC
5th Mar 2013 06:44
Foreign & Colonial Investment Trust has slashed its exposure to UK equities by a third since the start of the year, to 200m pounds, in anticipation of a weaker pound and a correction in equity markets worldwide. Amongst others, it has cut its holdings of stock in the following corporations: Vodafone
Read moreFriday broker round-up UPDATE
22nd Feb 2013 07:12
Antofagasta: RBC upgrades from underperform to outperform. Ashmore Group: Citigroup raises target price from 330p to 355p upgrading to neutral. JP Morgan ups target price from 361p to 413p and maintains a neutral rating. Babcock International: Citigroup revises target price from 965p to 1185p and
Read moreSunday newspaper round-up: easyJet, Barclays, Man Group
10th Feb 2013 17:24
The Sunday Telegraph understands Sir Stelios, who with his family owns 36 per cent of easyJet´s shares, is to vote against the re-election of Sir Mike Rake, the Chairman, as well as against the board's remuneration report. In addition, he will abstain against all 18 other resolutions on matters such
Read moreThursday broker round-up UPDATE
7th Feb 2013 07:14
African Barrick Gold: Deutsche Bank shifts target price from 415p to 410p, while its hold recommendation is maintained. Ashmore Group: Canaccord Genuity moves target price from 315p to 399p and upgrades to buy. Atkins: JP Morgan takes target price from 859p to 893p and reiterates an overweight rat
Read moreThursday tips round-up: Wolfson, Glaxo, Lamprell
7th Feb 2013 06:57
Accident-prone Wolfson has stumbled again. Fourth-quarter trading was encouraging in terms of revenues, but disappointing, for understandable reasons, on margins. The story at Wolfson has been of a recovery from the annus horribilis of 2008, when Apple scrapped its contract to supply relatively unso
Read moreLondon close: Political uncertainty caps gains
6th Feb 2013 16:48
If in the best of times equities would find it hard going to continue advancing in the face of higher bond yields and rising energy quotes then even more so now that political uncertainty in the Eurozone, namely in Italy this time, as well as in the US is re-emerging a little. Thus, in the ear
Read moreGlaxoSmithKline sales contract by 1.0 per cent in 2012
6th Feb 2013 13:06
FTSE-100 listed pharmaceutical giant GlaxoSmithKline (GSK) has posted a 1.0 per cent decline in its annual turnover for the year ending December 31st, according to a financial update issued by the company on Wednesday. Turnover contracted to £26,431m with the adverse impact to performance in 2012 b
Read moreLondon midday: Stocks holding higher for now
6th Feb 2013 12:00
By the midday mark the Footsie was continuing to trade slightly higher, tracking overnight gains on Wall Street and in Tokyo. The latter came in response to news that Bank of Japan Governor, Masaaki Shirakawa, will step down on March 19th, almost three weeks ahead of schedule, which some observers
Read moreWednesday preview: GlaxoSmithKline to report difficult quarter, analysts say
5th Feb 2013 15:01
Healthcare giant GlaxoSmithKline is expected to report 'another difficult quarter' when the company unveils its latest results Wednesday, according to analysts. The pharmaceuticals group will post its full-year and fourth quarter financials, a day after announcing it increased its stake in its Indi
Read moreGlaxo invests half a billion pounds in Indian consumer healthcare division
5th Feb 2013 07:52
Pharmaceuticals group GlaxoSmithKline (GSK) has upped its stake in its Indian consumer healthcare subsidiary by investing over half a billion pounds in the unit. GSK, which first announced an open offer back in November, has now raised its stake in the Indian publicly-listed division from 43.2% to
Read moreTuesday broker round-up UPDATE
29th Jan 2013 07:26
Anglo American: JP Morgan takes price target from 1630p to 1680p, while its underweight rating remains unchanged. ARM Holdings: Jefferies raises target price from 693p to 805p keeping a hold recommendation. Astra Zaneca: Barclays ups target price from 3100p to 3200p and retains an equal-weight rat
Read moreWednesday broker round-up UPDATE
16th Jan 2013 07:16
Anglo American: Goldman Sachs reduces target price from 1650p to 1500p and reiterates its sell recommendation. Antofagasta: Goldman Sachs ups target price from 1100p to 1120p and still recommends to sell. ARM Holdings: UBS increases target price from 750p to 900p, while downgrading to neutral. As
Read moreGlaxoSmithKline submits new diabetes drug for US approval
14th Jan 2013 10:38
Pharma giant GlaxoSmithKline (GSK) submitted its latest treatment for type two diabetes to the US Food and Drug Administration (FDA) for regulatory approval. The firm said albiglutide BLA, an investigational once-weekly treatment for adult patients, was not yet approved as a treatment for type two
Read moreMonday newspaper round-up: AstraZeneca, North Sea jobs, Glaxo...
14th Jan 2013 06:56
The Science Minister has lobbied the NHS to increase its use of an AstraZeneca heart medicine, amid mounting political concern about the drugs company's commitment to British jobs. David Willetts has urged health officials to accelerate the uptake of Brilique, a blood thinner used to treat patients
Read more